Dogwood Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Stockholders' Equity (Deficit) (Details)

Stockholders' Equity (Deficit) (Details)								1 Months Ended	3 Months Ended	12 Months Ended
Stockholders' Equity (Deficit) (Details)	Nov. 21, 2025 shares	Sep. 29, 2025 $ / shares shares	Apr. 07, 2025 shares	Mar. 14, 2025 USD ($)	Mar. 12, 2025 $ / shares shares	Oct. 17, 2024	May 22, 2024 USD ($)	Sep. 30, 2025 USD ($) shares	Dec. 31, 2025 USD ($) $ / shares shares	Dec. 31, 2025 USD ($) item $ / shares shares	Nov. 28, 2025 USD ($)	Mar. 31, 2025 USD ($) shares	Dec. 31, 2024 $ / shares shares	Oct. 31, 2024 shares	Oct. 07, 2024 $ / shares	May 19, 2024 $ / shares shares	Dec. 31, 2023 $ / shares shares	Dec. 16, 2020 $ / shares shares
Stockholders' Equity
Preferred stock authorized														2,000,000			2,000,000
Preferred stock, par value (in dollars per share) \| $ / shares																	$ 0.0001
Temporary equity, shares authorized									2,104	2,104			2,270
Temporary equity, shares issued									2,103.1494	2,103.1494			2,213.8044
Temporary equity, shares outstanding									0	0			2,213.8044
Dividends payable \| $												$ 1,770,767
Waiver and conversion of preferred stock \| $								$ 5,500,000		$ 70,126,957
Waiver of cash settlement and related repurchase rights for series A preferred stock								166
Common stock authorized									43,000,000	43,000,000			43,000,000					43,000,000
Common stock, par value (in dollars per share) \| $ / shares									$ 0.0001	$ 0.0001			$ 0.0001					$ 0.0001
Net proceeds from issuance of common stock \| $										$ 86,366
Common stock reserved for the future issuance									13,248,766	13,248,766
Number of votes per common stock \| item										1
Preferred Stock Excluding Series A and Series A-1 Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized									1,997,254	1,997,254			1,997,730
Series A Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock converted to common stock	10,000
Temporary equity, shares authorized									2,270	2,270			2,270	2,270
Temporary equity, shares issued									2,269.1494	2,269.1494			2,213.8044
Temporary equity, shares outstanding									0	0			2,213.8044
Preferred stock dividend rate percentage										5.00%
Preferred stock dividend payment period			180 days							180 days
PIK dividend, shares			55.345
Percentage of original shares remaining issued and outstanding										30.00%
Series A1 Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized									285	285		285	0
Preferred stock, par value (in dollars per share) \| $ / shares					$ 0.0001
Preferred stock issued									284.2638	284.2638			0
Preferred stock outstanding									0	0			0
Preferred stock converted to common stock	10,000
Minimum percentage of preferred stock issued and outstanding										30.00%
Series A2 Convertible Preferred stock
Stockholders' Equity
Preferred stock authorized								190.0572	190.0572	190.0572			0
Preferred stock issued									190.0572	190.0572			0
Preferred stock outstanding									0	0			0
Preferred stock converted to common stock	10,000
Minimum percentage of preferred stock issued and outstanding										30.00%
Series A-2 Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized									190.0572	190.0572			0
Preferred stock issued									190.0572	190.0572			0
Preferred stock outstanding									0	0			0
Common stock, par value (in dollars per share) \| $ / shares									$ 0.0001	$ 0.0001			$ 0.0001
Series A Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized									166	166			0
Preferred stock, par value (in dollars per share) \| $ / shares									$ 0.0001	$ 0.0001			$ 0.0001
Preferred stock issued									166	166			0
Preferred stock outstanding									0	0			0
Common stock, par value (in dollars per share) \| $ / shares		$ 0.0001
Series A Non-Voting Convertible Preferred Stock \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Common stock, par value (in dollars per share) \| $ / shares		0.0001
Pharmagesic Holdings Inc.
Stockholders' Equity
Preferred stock, par value (in dollars per share) \| $ / shares															$ 0.0001
Number of contingent value rights issuable for each common share						1
Contingent value rights agreement term						7 years
Percentage of upfront payment to which holders are entitled						87.75%
Percentage ownership of outstanding rights that entitles holder to audit and enforcement						30.00%
Serpin Pharma \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Common stock, par value (in dollars per share) \| $ / shares		$ 0.0001
Total consideration paid		191,017
Serpin Pharma \| Series A-2 Non-Voting Convertible Preferred Stock \| License for SP16 Development
Stockholders' Equity
Total consideration paid		89.5939
Serpin Registration Rights Agreement \| Common Stock \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Total consideration paid		191,017
Serpin Registration Rights Agreement \| Series A-2 Non-Voting Convertible Preferred Stock \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Total consideration paid		89.5939
Tungsten Advisors \| Series A-2 Non-Voting Convertible Preferred Stock \| License for SP16 Development
Stockholders' Equity
Total consideration paid		10.8694
Public Offering \| Maxim Group LLC
Stockholders' Equity
Share price \| $ / shares																$ 5
Gross proceeds from issuance of shares \| $							$ 1,700,000
Net proceeds from issuance of common stock \| $							$ 1,400,000
Issuance of common stock at a public offering																340,000
Registered Direct Offering
Stockholders' Equity
No of shares issued					578,950
Offering price per share \| $ / shares					$ 8.26
Gross proceeds from issuance of shares \| $				$ 4,780,000
Net proceeds from issuance of common stock \| $				$ 4,250,000
At the market offering
Stockholders' Equity
Gross proceeds from issuance of shares \| $									$ 89,762
Aggregate offering price \| $											$ 8,558,712